New Cannabis Derivative Offers ‘Holy Grail’ Outcome in the Treatment of MS

Emerald Health, a Canadian cannabis pharmaceutical company, is developing what could be a “holy grail” treatment for sufferers of Multiple Sclerosis (MS).